Clemondo Group (CLEM) Q3 2025 earnings summary

Executive summary

• Net sales increased by 13% to SEK 65.3 million in Q3 2025 compared to Q3 2024, marking the fifth consecutive quarter of growth.

• All market areas except contract manufacturing contributed to growth; Medical Care led with 26% growth.

• Strategic investments in quality, procurement, and digitalization increased costs by SEK 4.6 million in the quarter.

• Peter Andersson appointed as new CEO, effective February 2026.

• Awarded a significant contract in the Femklövern procurement, valued at SEK 13–14 million.

Financial highlights

• EBITDA was SEK 5.1 million (down from SEK 6.1 million in Q3 2024), with an EBITDA margin of 7.7% (10.4%).

• EBIT was SEK 1.4 million (down from SEK 2.3 million), EBIT margin 2.1% (4.0%).

• Net income after tax was SEK 0.7 million (down from SEK 1.7 million).

• Earnings per share were SEK 0.05 (down from SEK 0.12).

• Cash flow from operations after working capital changes was SEK 2.1 million (up from SEK -3.4 million).

Outlook and guidance

• Organic growth for the first nine months exceeded financial targets.

• Management sees strong prospects for continued growth despite challenging macroeconomic conditions.